CD274 and neoplasm: In previously treated patients with advanced nonsquamous NSCLC, nivolumab conferred higher objective response rates in the groups of patients whose tumors exhibited PD‐L1 expression levels of >1%, >5%, and >10%, but not in patients with PD‐L1 expression in <1% of their tumor cells (31% for the >1% group and 12% for the <1% group).